Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vistusertib Monotherapy in TSC1/2 Mutated Refractory Solid Cancer
NCT03166176Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vistusertib in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate at 12 months. Planned start Mar 2018; status: withdrawn.
02
Drugs
vistusertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03166176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166176.